Annual report pursuant to Section 13 and 15(d)

Collaborative, Licensing and Other Arrangements (Details)

v2.4.0.6
Collaborative, Licensing and Other Arrangements (Details)
Share data in Millions, except Per Share data, unless otherwise specified
12 Months Ended 36 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 3 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 1 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2010
USD ($)
Dec. 31, 2012
Dec. 31, 2003
USD ($)
Dec. 31, 2012
License Arrangement [Member]
Dec. 31, 2011
Servier [Member]
Up-front Payment Arrangement [Member]
USD ($)
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
Dec. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
Oct. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2010
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2009
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Sep. 30, 2008
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 3 [Member]
USD ($)
Jul. 31, 2006
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 3 [Member]
USD ($)
Dec. 31, 2007
Pfizer Inc. [Member]
License Arrangement [Member]
USD ($)
Jan. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
Jan. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
EUR (€)
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
Dec. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier [Member]
Sales And Development Milestones [Member]
USD ($)
Dec. 31, 2010
Collaborative Arrangement [Member]
Servier [Member]
Up-front Payment Arrangement [Member]
USD ($)
Sep. 30, 2010
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
USD ($)
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
Development Milestone [Member]
USD ($)
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
Sales Milestone [Member]
USD ($)
Feb. 28, 2009
Collaborative Arrangement [Member]
Takeda [Member]
Nov. 30, 2006
Collaborative Arrangement [Member]
Takeda [Member]
Dec. 31, 2012
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
Dec. 31, 2011
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
Dec. 31, 2010
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
Dec. 31, 2012
Collaborative Arrangement [Member]
Takeda [Member]
Development Milestone [Member]
USD ($)
Feb. 28, 2009
Collaborative Arrangement [Member]
Takeda [Member]
Sales Milestone [Member]
USD ($)
Nov. 30, 2006
Collaborative Arrangement [Member]
Takeda [Member]
Sales Milestone [Member]
USD ($)
Nov. 30, 2008
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
Dec. 31, 2012
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
Nov. 30, 2008
Collaborative Arrangement [Member]
Novartis [Member]
Development Milestone [Member]
USD ($)
Sep. 30, 2009
Collaborative Arrangement [Member]
Arana Therapeutics Limited [Member]
USD ($)
Sep. 30, 2010
Collaborative Arrangement [Member]
Arana Therapeutics Limited [Member]
USD ($)
Sep. 30, 2009
Collaborative Arrangement [Member]
Arana Therapeutics Limited [Member]
USD ($)
Sep. 30, 2009
Collaborative Arrangement [Member]
Arana Therapeutics Limited [Member]
Sales Milestone [Member]
USD ($)
Oct. 31, 2009
Collaborative Arrangement [Member]
The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member]
USD ($)
Dec. 31, 2010
Collaborative Arrangement [Member]
The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member]
USD ($)
Dec. 31, 2009
Collaborative Arrangement [Member]
The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member]
USD ($)
Oct. 31, 2009
Collaborative Arrangement [Member]
The Chemo-Sero-Therapeutic Research Institute "Kaketsuken" [Member]
Sales Milestone [Member]
USD ($)
Mar. 31, 2003
Collaborative Arrangement [Member]
Genentech, Inc. ("Genentech") [Member]
Oct. 31, 2003
Collaborative Arrangement [Member]
Genentech, Inc. ("Genentech") [Member]
Convertible Preferred Stock [Member]
USD ($)
Oct. 31, 2003
Collaborative Arrangement [Member]
Genentech, Inc. ("Genentech") [Member]
Common Stock [Member]
USD ($)
Dec. 31, 2012
Collaborative Arrangement [Member]
Pfizer Inc. [Member]
Sales Milestone [Member]
USD ($)
Sep. 30, 2006
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
Apr. 30, 2006
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
Dec. 31, 2012
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
USD ($)
Dec. 31, 2011
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
USD ($)
Dec. 31, 2010
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
USD ($)
Sep. 30, 2006
Non-arrangement Transactions [Member]
AVEO Pharmaceuticals, Inc. ("AVEO") [Member]
Sales Milestone [Member]
USD ($)
Sep. 30, 2010
Non-arrangement Transactions [Member]
UCB Celltech [Member]
USD ($)
Dec. 31, 2010
Non-arrangement Transactions [Member]
UCB Celltech [Member]
USD ($)
Dec. 31, 2011
Non-arrangement Transactions [Member]
Pfizer Inc. [Member]
Development Milestone [Member]
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                                                                                                        
Deferred revenue, current                                               $ 15,000,000                                                                        
Non-refundable upfront payment received                                     15,000,000                                                                                  
Period for recognizing deferred revenue                                         8 months                                                                              
Proceeds from loan                                     19,500,000 15,000,000                                                                                
Total contract amount awarded                   28,000,000         64,800,000   16,300,000                                             6,000,000   6,000,000   8,000,000                                
Contractual term               5 years     3 years         3 years                                                                                        
Increase in deferred revenue                         900,000 1,400,000   2,000,000                                                                                        
Recognition of deferred revenue             14,900,000 2,500,000 100,000   6,600,000 18,600,000 21,200,000     2,000,000                             1,200,000 2,000,000 3,600,000                                                      
Future initial research and development expenses to be funded by counterparty                                         50,000,000                                                                              
Future other expenses to be funded by counterparty (in hundredths)                                         50.00%                                                                              
Licensing and collaboration agreement revenue 5,727,000 17,991,000 2,182,000                                   14,500,000 34,200,000                                                               100,000 100,000 900,000     4,200,000  
Future milestone payments, maximum                                             470,000,000                       3,250,000 19,000,000     14,000,000       3,000,000       200,000                          
Future milestone payments, repurchase option not exercised, maximum                                             810,000,000                                                                          
Number of fixed-dose combination product candidates included in a portfolio of antihypertensive products from Servier                                                   3                                                                    
License fees paid                                                 1,500,000                                                                      
Amount due upon achievement of milestone                                                     8,500,000 15,100,000                                                                
Future milestone payments with each additional future qualifying product candidate development, maximum                                                                   20,750,000                                                   1,700,000
Royalty right expiration period                                                         10 years 13 years 6 months             20 years     5 years       15 years               15 years                
Proceeds from collaborators                                                                         6,200,000       2,000,000 4,000,000     2,000,000 6,000,000                            
Reduction in debt under restructured agreement                                                                         7,500,000                                              
Number of ongoing product programs with potential royalty right milestone payments                                                                             2                                          
Maximum borrowing capacity under agreement                                                                           50,000,000                                            
Research and development expenses funded through loan facility, maximum (in hundredths)                                                                           75.00%                                            
Number of versions of original AV-299 created                                                                                                         4              
Additional future milestone payments                                                                                                     8,300,000           6,300,000      
Proceeds from sale of royalty interest                                                                                                                   4,000,000    
Eligible share of operating profits and losses (in hundredths)                                                                                               25.00%                        
Repayment of loan                                                                                                 29,600,000                      
Number of shares of common stock issuable upon conversion (in shares)                                                                                                   0.3                    
Par value of common shares issuable upon conversion (in dollars per share)                                                                                                   $ 116.25                    
Liquidation preference         29,600,000                                                                                       29,600,000                      
Number of licenses granted, minimum           60                                                                                                            
Proceeds from license fees received                                   $ 30,000,000                                                                                    
Number of undisclosed product candidates with milestone payments received       6